Emergent BioSolutions receives a $62.4 million contract modification to supply Botulism Antitoxin for U.S. public health protection.
Quiver AI Summary
Emergent BioSolutions Inc. announced the award of a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) to supply its Botulism Antitoxin Heptavalent (BAT®). This modification updates an existing 10-year contract to ensure the availability of BAT®, which is essential for treating botulism resulting from exposure to various serotypes of botulinum neurotoxin in both adults and children. Paul Williams from Emergent highlighted the importance of this government commitment to stockpile BAT® for public health protection against biological threats. The announcement underscores Emergent's role in delivering vital medical countermeasures, improving emergency preparedness, and safeguarding public health.
Potential Positives
- Emergent BioSolutions has secured a significant $62.4 million contract modification from the U.S. government, demonstrating strong governmental support for its products.
- The continuation of the contract for BAT® reinforces the company's role in providing critical medical countermeasures against potential biological threats, enhancing its market position.
- This contract modification highlights Emergent's commitment to public health and emergency preparedness, promoting the company's reputation as a reliable partner in health security.
- The award supports the long-term operational capabilities of Emergent BioSolutions, emphasizing the importance of their North American supply chain in delivering life-saving solutions.
Potential Negatives
- Severe hypersensitivity reactions including anaphylaxis, as well as potential transmissible infectious agents in BAT may raise safety concerns among healthcare providers and patients.
- The acknowledgment of limited safety data for pediatric and geriatric populations might limit the drug's use in critical demographics.
- The reliance on government contracts for product demand highlights potential vulnerability to changes in government procurement priorities or funding.
FAQ
What is the purpose of the $62.4 million contract modification?
The contract modification is for Emergent BioSolutions to supply BAT®, an antitoxin for treating botulism.
How long is the contract with ASPR?
The contract with the Administration for Strategic Preparedness and Response is a 10-year agreement.
What are the uses of BAT®?
BAT® is used for the treatment of symptomatic botulism after exposure to botulinum neurotoxin serotypes.
What are common side effects of BAT®?
Common side effects include headache, nausea, pruritus, urticaria, and pyrexia among others.
Who is the target population for BAT®?
BAT® is indicated for both adults and pediatric patients following exposure to botulinum neurotoxin.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EBS Insider Trading Activity
$EBS insiders have traded $EBS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- NEAL FRANKLIN FOWLER sold 35,000 shares for an estimated $204,050
- KATHRYN C ZOON sold 10,000 shares for an estimated $57,300
- KEITH KATKIN sold 7,844 shares for an estimated $49,417
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EBS Hedge Fund Activity
We have seen 89 institutional investors add shares of $EBS stock to their portfolio, and 84 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OAK HILL ADVISORS LP added 1,113,338 shares (+inf%) to their portfolio in Q4 2024, for an estimated $10,643,511
- MILLENNIUM MANAGEMENT LLC added 1,020,582 shares (+68.9%) to their portfolio in Q1 2025, for an estimated $4,960,028
- LSV ASSET MANAGEMENT added 809,591 shares (+3748.1%) to their portfolio in Q1 2025, for an estimated $3,934,612
- INVESCO LTD. removed 791,948 shares (-51.4%) from their portfolio in Q1 2025, for an estimated $3,848,867
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 706,959 shares (-54.8%) from their portfolio in Q1 2025, for an estimated $3,435,820
- ACADIAN ASSET MANAGEMENT LLC added 631,794 shares (+313.5%) to their portfolio in Q1 2025, for an estimated $3,070,518
- DIMENSIONAL FUND ADVISORS LP added 492,579 shares (+44.6%) to their portfolio in Q1 2025, for an estimated $2,393,933
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EBS Analyst Ratings
Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 12/30/2024
To track analyst ratings and price targets for $EBS, check out Quiver Quantitative's $EBS forecast page.
Full Release
GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS) for BAT
®
[Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT
®
, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pediatric patients.
“The ongoing commitment by the U.S. government to stockpile BAT
®
reinforces the importance of Emergent's medical countermeasures to help protect military and civilian populations,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “We are proud to harness our North American supply chain and capabilities to deliver life-saving solutions that safeguard public health and strengthen global emergency preparedness.”
This update is a critical step toward preserving access to medical countermeasures to address potential biological threats from botulism. The types and quantities of products that should be maintained in a stockpile will depend on the population requiring protection, the products available for meeting the threat, as well as government resources and priorities.
About BAT
®
[Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]
BAT
®
is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. The effectiveness of BAT is based solely on efficacy studies conducted in animal models of botulism.
The Warnings and Precautions for BAT include:
Severe hypersensitivity reactions, including anaphylaxis, as well as delayed allergic reactions, including serum sickness may occur following BAT administration. Prepare for monitoring and management of allergic reactions.
Infusion reactions. These reactions may be related to the infusion rate of BAT.
Interference with blood glucose testing. Because BAT contains maltose, interference with non-glucose specific blood sugar testing systems can occur. Use glucose-specific testing systems.
Transmissible infections agents. BAT is made from equine plasma and may contain infectious agents, e.g. viruses.
There is no human or animal data for use of BAT during pregnancy. BAT should only be given to pregnant and nursing women if the potential benefits outweigh the potential risks. It is not known whether BAT is excreted in human milk. The safety and efficacy of BAT has not been established in pediatric and geriatric populations. Only limited safety data exists for pediatric populations.
The most common adverse reactions observed in ≥5% of healthy volunteers in clinical trials were headache, nausea, pruritus, and urticaria. The most common adverse reactions reported in ≥1% of patients in a clinical study were pyrexia, rash, chills, nausea, and edema. One serious adverse reaction of hemodynamic instability was observed in one patient in the clinical study.
Please see full
Prescribing Information
for BAT for additional safety information.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our
website
and follow us on
LinkedIn
,
X
,
Instagram
,
Apple Podcasts
and
Spotify
.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the development, availability, and government procurement of BAT
®
are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
